{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:29:28Z","timestamp":1785288568629,"version":"3.55.0"},"reference-count":69,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although people living with human immunodeficiency virus and other comorbidities are expected to experience more grievous consequences with corona virus disease 2019 (COVID\u201019), recent cohort studies did not indicate this. Antiretrovirals (ARVs) might have a prophylactic role in these patients. The purpose of this study was to review the most recently published articles on the possible role of ARVs for pre\u2010 or postexposure prophylaxis against COVID\u201019. From June to October 2020, we searched scientific databases using specific key words to identify ongoing trials or articles published before October 2020 investigating any subgroups of ARVs for prophylaxis against COVID\u201019. Apart from molecular docking studies, in vitro, animal, and human studies are very limited for evaluating the prophylactic role of ARVs against severe acute respiratory syndrome\u2010corona virus 2 (SARS\u2010CoV\u20102) infection. According to our findings, there is no definite evidence to support use of protease inhibitors for this purpose, despite the promising results of molecular studies and limited clinical evidence for ritonavir\u2010boosted lopinavir, darunavir, and nelfinavir when used early in the course of the disease. Nucleotide\/nucleoside reverse\u2010transcriptase inhibitors (NRTI) also have shown binding affinity to main enzymes of SARS\u2010CoV\u20102 in molecular, in vitro, and animal studies. NRTIs like tenofovir and emtricitabine might exhibit a prophylactic role against SARS\u2010CoV\u20102 infection. In conclusion, currently there is no evidence to justify the use of ARVs for prophylaxis against COVID\u201019.<\/jats:p>","DOI":"10.1002\/jcph.1788","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T06:44:24Z","timestamp":1605941064000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antiretrovirals for Prophylaxis Against COVID\u201019: A Comprehensive Literature Review"],"prefix":"10.1002","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-8190","authenticated-orcid":false,"given":"Golbarg","family":"Alavian","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-5619","authenticated-orcid":false,"given":"Kasra","family":"Kolahdouzan","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department Radiation Oncology Research Center Imam Khomeini Hospital Complex Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-9379","authenticated-orcid":false,"given":"Masoud","family":"Mortezazadeh","sequence":"additional","affiliation":[{"name":"Internal Medicine Department Sina Hospital Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-6186","authenticated-orcid":false,"given":"Zahra Sadat","family":"Torabi","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery Department Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,6]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization. Weekly epidemiological update coronavirus disease 2019 (COVID\u201019).https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update---27-october-2020. Published October 27 2020. Accessed October 27 2020."},{"key":"e_1_2_10_3_1","article-title":"Risk of COVID\u201019 among frontline healthcare workers and the general community: a prospective cohort study","author":"Nguyen LH","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"e_1_2_10_5_1","article-title":"Clinical characteristics and outcomes in people living with HIV hospitalized for COVID\u201019","author":"Shalev N","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_10_6_1","article-title":"A survey for COVID\u201019 among HIV\/AIDS patients in two Districts of Wuhan, China","author":"Guo W","year":"2020","journal-title":"AIDS Patients in Two Districts of Wuhan"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3689"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa579"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-017-0356-x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182185276"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_639_20"},{"key":"e_1_2_10_12_1","article-title":"Prevalence, clinical characteristics and treatment outcomes of HIV and SARS\u2010CoV\u20102 co\u2010infection: a systematic review and meta\u2010analysis","author":"Baluku JB","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/386340"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2018.09.005"},{"key":"e_1_2_10_15_1","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv Z","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.0c00160"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1752802"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","unstructured":"CopertinoDCJr LimaB DuarteR et\u00a0al.Antiretroviral drug activity and potential for pre\u2010exposure prophylaxis against COVID\u201019 and HIV infection.https:\/\/chemrxiv.org\/ndownloader\/articles\/12250199\/versions\/1\/export_pdf. Published2020. Accessed October 22 2020.","DOI":"10.26434\/chemrxiv.12250199"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32013-4"},{"key":"e_1_2_10_21_1","article-title":"Repurposed antiviral drugs for COVID\u201019; interim WHO SOLIDARITY trial results","author":"Pan H","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.039"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320935306"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104786"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104866"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1909"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173634"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa190"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa195"},{"key":"e_1_2_10_30_1","unstructured":"COVID\u201019 Ring\u2010based Prevention Trial With Lopinavir\/Ritonavir.https:\/\/ClinicalTrials.gov\/show\/NCT04321174. Accessed October 15 2020."},{"key":"e_1_2_10_31_1","unstructured":"Chemoprophylaxis of SARS\u2010CoV\u20102 Infection (COVID\u201019) in Exposed Healthcare Workers.https:\/\/ClinicalTrials.gov\/show\/NCT04328285. Accessed October 15 2020."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.03.025"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S259152"},{"key":"e_1_2_10_34_1","unstructured":"NA\u2010831 Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID\u201019 Infection.https:\/\/ClinicalTrials.gov\/show\/NCT04452565. Accessed October 15 2020."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa241"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.05.085"},{"key":"e_1_2_10_37_1","unstructured":"Darunavir\/Cobicistat vs. Lopinavir\/Ritonavir in COVID\u201019 Pneumonia in Qatar.https:\/\/ClinicalTrials.gov\/show\/NCT04425382."},{"key":"e_1_2_10_38_1","unstructured":"Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID\u201019 Infection.https:\/\/ClinicalTrials.gov\/show\/NCT04435587."},{"key":"e_1_2_10_39_1","unstructured":"Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID\u201019.https:\/\/ClinicalTrials.gov\/show\/NCT04252274. Accessed October 15 2020."},{"key":"e_1_2_10_40_1","unstructured":"Various Combination of Protease Inhibitors Oseltamivir Favipiravir and Hydroxychloroquine for Treatment of COVID\u201019 : A Randomized Control Trial.https:\/\/ClinicalTrials.gov\/show\/NCT04303299. Accessed October 12 2020."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.05.019"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104826"},{"key":"e_1_2_10_43_1","unstructured":"Treatment of non\u2010severe confirmed cases of COVID\u201019 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV\u20102 Study).https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2020-001031-27. Accessed October 25 2020."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101646"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00326"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25985"},{"key":"e_1_2_10_47_1","unstructured":"Impact of long\u2010term protease inhibitors in patients living with HIV on the incidence of COVID\u201019 (COVIP).https:\/\/ClinicalTrials.gov\/show\/NCT04357639. Accessed October 12 2020."},{"key":"e_1_2_10_48_1","first-page":"1","article-title":"In\u2010silico drug repurposing and molecular dynamics puzzled out potential SARS\u2010CoV\u20102 main protease inhibitors","author":"Ibrahim MAA","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443090-00003"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02240218"},{"key":"e_1_2_10_51_1","unstructured":""},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq447"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00392"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117592"},{"key":"e_1_2_10_55_1","author":"Jockusch S","year":"2020","journal-title":"bioRxiv"},{"issue":"8","key":"e_1_2_10_56_1","first-page":"1552","article-title":"Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS\u2010CoV\u20102","volume":"31","author":"Clososki GC","year":"2020","journal-title":"J Braz Chem Soc"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.05.012"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01114-20"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(98)00017-3"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa455"},{"key":"e_1_2_10_61_1","unstructured":"Randomized Clinical Trial for the Prevention of SARS\u2010CoV\u20102 Infection (COVID\u201019) in Healthcare Personnel.https:\/\/ClinicalTrials.gov\/show\/NCT04334928. Accessed October 14 2020."},{"key":"e_1_2_10_62_1","unstructured":"Daily Regimen of Tenofovir\/Emtricitabine as Prevention for COVID\u201019 in Health Care Personnel in Colombia.https:\/\/ClinicalTrials.gov\/show\/NCT04519125. Accessed October 15 2020."},{"key":"e_1_2_10_63_1","unstructured":"TAF\/FTC for Pre\u2010exposure Prophylaxis of COVID\u201019 in Healthcare Workers (CoviPrep Study).https:\/\/ClinicalTrials.gov\/show\/NCT04405271. Accessed October 12 2020."},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1004.030458"},{"key":"e_1_2_10_65_1","article-title":"HIV and risk of COVID\u201019 death: a population cohort study from the Western Cape Province, South Africa","author":"Davies MA","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160087"},{"key":"e_1_2_10_67_1","first-page":"1","article-title":"Targeting SARS\u2010CoV\u20102: a systematic drug repurposing approach to identify promising inhibitors against 3C\u2010like proteinase and 2'\u2010O\u2010ribose methyltransferase","author":"Khan RJ","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17495-9"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2020.06.016"},{"key":"e_1_2_10_70_1","article-title":"COVID\u201019 attack rate in HIV\u2010infected patients and in PrEP users","author":"Charre C","year":"2020","journal-title":"AIDS"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:26:45Z","timestamp":1693625205000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,6]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/jcph.1788"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1788","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,6]]},"assertion":[{"value":"2020-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}